非経口栄養の世界市場 - 市場考察、競合情勢、市場予測（2030年）

世界の非経口栄養の市場規模は、2023年に60億8,435万米ドルであり、2030年までに86億1,469万米ドルに達する可能性が高く、2024年～2030年の予測期間にCAGRで6.04％の成長が見込まれます。市場は主に、小児の栄養不良の有病率の増加により、大幅な市場成長を示しています。栄養不良につながる早産児の増加、非経口栄養に関する政府の取り組みや新しいガイドラインの発行の増加、がん、糖尿病などのさまざまな代謝性・慢性疾患の有病率の増加が、今後数年間の非経口栄養市場を後押しする見通しです。さらに、非経口栄養関連機器の承認と発売の急増に伴う研究開発活動の増加などの要因が、非経口栄養の必要性を生み出し、2024年～2030年の予測期間に大幅なCAGRで市場を牽引する見込みです。

非経口栄養の市場力学

世界保健機関（WHO）が2024年に提供したデータによると、2022年に世界で18歳以上の成人3億9,000万人が体重不足でした。さらに、1億9,000万人の子供と青少年がやせており、これは年齢に対するBMIが基準中央値より2標準偏差以上低いと定義されています。さらに2022年、1億4,900万人の5歳未満の子供が発育阻害の影響を受けています。栄養不足は、子供たちが一般的な感染症で死亡するリスクを高め、そのような感染症の頻度と重症度を増加させ、回復を遅らせます。

UNICEFの2023年のレポートによると、2022年、5歳未満の子供のうち1億4,810万人が発育不良であり、少なくとも4,500万人が、その年のいずれかの時点で衰弱を経験していました。同時に、世界の5歳未満の子供の過体重の有病率は上昇し、2022年に3,300万人から3,700万人に増加しました。また、消耗症を患う子供の半数以上が南アジアに、4分の1近くがサブサハラアフリカに住んでおり、重度の消耗症に罹患している子供についても同様の割合でした。14.7％という南アジアの発育阻害の有病率は、適切な治療プログラムによる介入を必要とする深刻な状況を表しています。

このように、上記の資料は、世界のさまざまな地域で栄養不足または栄養不良の有病率が上昇していることを強調しており、これは非経口経路を通じて栄養を供給することで治すことができるため、予測期間に非経口栄養の需要が増加することにつながります。

WHO（2022）によると、毎年1,500万人の赤ちゃんが早産で生まれていると推定されており、これは10人に1人以上の割合です。また、早産の合併症により毎年約100万人の子供が死亡しています。超低出生体重（VLBW）の早産児には、出生後の発育不全を防ぎ、神経発達の転帰を改善するために、分娩後できるだけ早く非経口栄養を開始しなければなりません。したがって、早産児の増加により非経口栄養の需要が増加し、予測期間に市場成長をかつてない高みへと押し上げることになります。

さらに、研究開発活動の活発化、世界中で拡大する製品の上市と承認、パイプラインにある多数の非経口栄養ソリューションの存在、非経口栄養の主要企業による戦略的活動は、非経口栄養市場を強化します。例えば2021年2月、世界的医療企業であるFresenius Kabiは、オーストリアの施設を拡張する計画を発表しました。同社は2023年までに6,940万米ドル超を投資し、欧州のグラーツにある生産工場とヴェルンドルフ近郊のパッケージングセンターの生産能力を拡大し、インフラをアップグレードする予定です。

したがって、2024年～2030年の予測期間に上記の要因が総合的に非経口栄養市場全体を牽引します。

しかし、栄養に関する認識不足や厳しい承認プロセスなどが、非経口栄養市場の成長にとっての課題となる可能性があります。

北米が非経口栄養市場全体を独占すると予測されます。

すべての地域の中で、北米が2023年に非経口栄養市場を独占し、2024年から2030年までの予測期間も同様である見込みです。

これは、同地域における栄養不良や慢性疾患の有病率の増加によるものと考えられます。さらに、慢性疾患に罹患しやすい老年人口の増加、製品開発活動の活発化、栄養不良とその管理に関する取り組みの高まり、非経口栄養ソリューションの発売の増加、同地域における主要市場企業のプレゼンスなどが、北米の非経口栄養市場の成長に寄与する主な要因です。

当レポートでは、世界の非経口栄養市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 非経口栄養市場レポートのイントロダクション

第2章 非経口栄養市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 非経口栄養市場の主な要因の分析

• 非経口栄養市場の促進要因
• 非経口栄養市場の抑制要因と課題
• 非経口栄養市場の機会

第6章 非経口栄養市場のポーターのファイブフォース分析

第7章 非経口栄養市場の評価

• 栄養素タイプ別
  • 炭水化物
  • 非経口脂肪乳剤
  • 単回投与アミノ酸溶液
  • 微量元素
  • ビタミン・ミネラル
• エンドユーザー別
  • 子供・新生児
  • 成人
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 非経口栄養市場の企業と製品のプロファイル

• B. Braun SE
• Fresenius Kabi India Pvt. Ltd
• Baxter
• Otsuka Pharmaceutical India Pvt. Ltd
• Pfizer Inc
• Grifols, S.A.
• JW Pharmaceutical
• Aculife Healthcare
• Kelun
• American Regent, Inc.
• EuroLife Healthcare Pvt. Ltd
• SGD Pharma
• icumedical
• Generic Specialties
• Vifor Pharma Management Ltd.
• Amanta Healthcare
• Anhui Medipharm Co, Ltd

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Parenteral Nutrition Market in Global (2021-2030)
• Table 3: Parenteral Nutrition Market in Global by Nutrient Type (2021-2030)
• Table 4: Parenteral Nutrition Market in Global by End-User (2021-2030)
• Table 5: Parenteral Nutrition Market in Global by Geography (2021-2030)
• Table 6: Parenteral Nutrition Market in North America (2021-2030)
• Table 7: Parenteral Nutrition Market in the United States (2021-2030)
• Table 8: Parenteral Nutrition Market in Canada (2021-2030)
• Table 9: Parenteral Nutrition Market in Mexico (2021-2030)
• Table 10: Parenteral Nutrition Market in Europe (2021-2030)
• Table 11: Parenteral Nutrition Market in France (2021-2030)
• Table 12: Parenteral Nutrition Market in Germany (2021-2030)
• Table 13: Parenteral Nutrition Market in United Kingdom (2021-2030)
• Table 14: Parenteral Nutrition Market in Italy (2021-2030)
• Table 15: Parenteral Nutrition Market in Spain (2021-2030)
• Table 16: Parenteral Nutrition Market in the Rest of Europe (2021-2030)
• Table 17: Parenteral Nutrition Market in Asia-Pacific (2021-2030)
• Table 18: Parenteral Nutrition Market in China (2021-2030)
• Table 19: Parenteral Nutrition Market in Japan (2021-2030)
• Table 20: Parenteral Nutrition Market in India (2021-2030)
• Table 21: Parenteral Nutrition Market in Australia (2021-2030)
• Table 22: Parenteral Nutrition Market in South Korea (2021-2030)
• Table 23: Parenteral Nutrition Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Parenteral Nutrition Market in the Rest of the World (2021-2030)
• Table 25: Parenteral Nutrition Market in the Middle East (2021-2030)
• Table 26: Parenteral Nutrition Market in Africa (2021-2030)
• Table 27: Parenteral Nutrition Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Parenteral Nutrition Market in Global (2021-2030)
• Figure 3: Parenteral Nutrition Market in Global by Nutrient Type (2021-2030)
• Figure 4: Parenteral Nutrition Market in Global by End-User (2021-2030)
• Figure 5: Parenteral Nutrition Market in Global by Geography (2021-2030)
• Figure 6: Parenteral Nutrition Market in North America (2021-2030)
• Figure 7: Parenteral Nutrition Market in the United States (2021-2030)
• Figure 8: Parenteral Nutrition Market in Canada (2021-2030)
• Figure 9: Parenteral Nutrition Market in Mexico (2021-2030)
• Figure 10: Parenteral Nutrition Market in Europe (2021-2030)
• Figure 11: Parenteral Nutrition Market in France (2021-2030)
• Figure 12: Parenteral Nutrition Market in Germany (2021-2030)
• Figure 13: Parenteral Nutrition Market in United Kingdom (2021-2030)
• Figure 14: Parenteral Nutrition Market in Italy (2021-2030)
• Figure 15: Parenteral Nutrition Market in Spain (2021-2030)
• Figure 16: Parenteral Nutrition Market in the Rest of Europe (2021-2030)
• Figure 17: Parenteral Nutrition Market in Asia-Pacific (2021-2030)
• Figure 18: Parenteral Nutrition Market in China (2021-2030)
• Figure 19: Parenteral Nutrition Market in Japan (2021-2030)
• Figure 20: Parenteral Nutrition Market in India (2021-2030)
• Figure 21: Parenteral Nutrition Market in Australia (2021-2030)
• Figure 22: Parenteral Nutrition Market in South Korea (2021-2030)
• Figure 23: Parenteral Nutrition Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Parenteral Nutrition Market in the Rest of the World (2021-2030)
• Figure 25: Parenteral Nutrition Market in the Middle East (2021-2030)
• Figure 26: Parenteral Nutrition Market in Africa (2021-2030)
• Figure 27: Parenteral Nutrition Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Parenteral Nutrition Market by Nutrient Type (Carbohydrates, Parenteral Lipid Emulsion, Single-Dose Amino Acid Solution, Trace Elements, and Vitamins & Minerals), End-User (Children & Newborns, and Adults), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of malnutrition across the globe and the increasing initiatives by public and private companies to create awareness regarding the malnutrition and parenteral nutrition

The parenteral nutrition market was valued at USD 6,084.35 million in 2023 and is likely to register a CAGR of 6.04% during the forecast period from 2024 to 2030 to reach USD 8,614.69 million by 2030. The parenteral nutrition market is observing substantial market growth primarily owing to the increasing prevalence of malnutrition among children. The rising number of premature births ultimately leading to malnutrition, rising government initiatives and issuance of new guidelines for parenteral nutrition, increasing prevalence of various metabolic & chronic conditions such as cancers, diabetes, and others, will aid in propelling the market of parenteral nutrition during the forthcoming years. In addition, the increasing research & developmental activities along with the surging approvals and launches of parenteral nutrition related devices, and other factors will create a requisite for parenteral nutrition, thus driving its market at a substantial CAGR during the forecast period from 2024 to 2030.

Parenteral Nutrition Market Dynamics:

According to data provided by the World Health Organization (WHO) in 2024; it stated that in 2022, 390 million adults aged 18 years and older worldwide were underweight. Additionally, 190 million children and adolescents were experiencing thinness, defined as a BMI for age more than two standard deviations below the reference median. Furthermore, in 2022; 149 million children under the age of 5 years were affected by stunting. Undernutrition puts children at greater risk of dying from common infections, increases the frequency and severity of such infections, and delays recovery.

The UNICEF 2023 report stated that in 2022, 148.1 million children under the age of 5 years were stunted, and at least 45.0 million experienced wasting at any given point during the year. Concurrently, the global prevalence of overweight in children under 5 years had risen, increasing from 33 million to 37 million in 2022. Also, more than half of all children affected by wasting lived in South Asia and nearly one-quarter in sub-Saharan Africa, with similar proportions for children affected by severe wasting. At 14.7 percent, South Asia's wasting prevalence represents a situation requiring a serious need for intervention with appropriate treatment programs.

Thus, the above sources highlight the rising prevalence of undernutrition or malnutrition in different regions of the world, which can be cured by providing nutrition through parenteral routes, thereby leading to an increased demand for parenteral nutrition during the forecast period.

As per the WHO (2022), it was estimated 15 million babies are born prematurely every year which is more than 1 in 10 babies. Also, approximately 1 million children die each year due to complications of preterm birth. Parenteral nutrition must be initiated as soon as possible after delivery in very low birth weight (VLBW) preterm infants to prevent postnatal growth failure and improve neurodevelopmental outcomes. Thus, the increasing number of preterm delivery will ultimately increase the demand for parenteral nutrition, propelling market growth to unprecedented heights during the forecast period.

Additionally, the growing research and developmental activities, expanding product launches and approvals around the world, presence of a robust number of parenteral nutrition solutions in pipeline, and strategic activities by key players in parenteral nutrition will bolster the market for parenteral nutrition. For instance, in February 2021, Fresenius Kabi, a global healthcare company, announced its plans to expand its Austrian facilities. The company will invest more than US$ 69.4 million through 2023 to expand capacity and upgrade infrastructure at its production plant in Graz and the packaging center nearby Werndorf, Europe.

Therefore, the factors stated above collectively will drive the overall parenteral nutrition market during the forecast period from 2024 to 2030.

However, lack of awareness regarding nutrition, stringent approval process, and others may prove to be challenging factors for parenteral nutrition market growth.

Parenteral Nutrition Market Segment Analysis:

Parenteral Nutrition Market by Nutrient Type (Carbohydrates, Parenteral Lipid Emulsion, Single-Dose Amino Acid Solution, Trace Elements, and Vitamins & Minerals), End-user (Children & Newborns and Adults), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the nutrient type segment of the parenteral nutrition market, the single-dose amino acid solution category is expected to have a significant revenue share in the year 2023. This is primarily owing to the rising demand and availability of single-dose amino acids in the market. Moreover, the growing launches and strategic investments, and other activities related to single-dose amino acids by key players in the market will act as key driving factors for the surging demand for single-dose amino acids.

Amino acids are highly used as a source of energy owing to their capability to treat mental fatigue, sprain, and muscle soreness among others. The single dose amino acids are used in the dietary management of inherited metabolic diseases providing specific amounts of amino acids that are unable to be achieved by dietary modification alone.

Moreover, single-dose amino acids are a range of pre-measured amino acids on a carbohydrate base, for use in dietary management of inborn errors of protein metabolism. Also, they are specifically developed to offer a more accurate and reliable method of administration requiring quantities of individual amino acids. Also, the pre-measured packets of single-dose amino acid solutions eliminate the need for weighing and provide convenience, thereby acting as key consumer factors responsible for their increased demand.

The newly available amino acid solutions possess fewer side effects, enhancing patient benefits. For example, Aminosyn, by Hospira, Inc., and Nirmin by Nirlife Pharma are a few of the single-dose amino acid solutions available in the market. The formulations of these mixed amino acids provide essential and nonessential amino acids; hence, the standard component acts as comprehensive parenteral nutrition for overall biological functioning.

Therefore, owing to all the above-mentioned advantages, the demand for single-dose amino acids is expected to increase; thereby this category is expected to witness considerable growth in the parenteral nutrition market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall parenteral nutrition market:

Among all the regions, North America was expected to dominate the parenteral nutrition market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.

This can be ascribed to the increasing prevalence of malnutrition and chronic diseases in the region. Further, the increasing geriatric population base prone to chronic diseases, rising product development activities, rising initiatives about malnutrition and its management, rising launches of parenteral nutrition solutions, presence of key market players in the region, and others are key factors that contribute to the growth of the parenteral nutrition market in North America.

According to the National Cancer Institute (2024), it estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, as per the Global Cancer Observatory's updated data (2024), in 2022, the US represented 89.1% of all cancer cases and Canada represented 10.9% of all cancer cases. The increasing incidence of cancers in the region will increase the demand for parenteral nutrition as people undergoing treatment for cancer need parenteral nutrition to help meet their nutritional needs. A special mixture of glucose, protein, fat, vitamins, and minerals is given through an IV into the veins.

The latest data provided by the source Feeding America Organization stated that approximately 40 million Americans suffer from hunger in the US every year, which also included more than 12 million children. These statistics reflect the impending diseases associated with malnourishment, which is one of the leading causative factors for the incrementing demand for parenteral nutrition in North America.

Moreover, the surging launches of parenteral nutrition solutions, regulatory approvals, and other activities such as acquisitions, and agreements, in the region will lead to its increased demand in the market. For instance, in March 2022, Fresenius Kabi announced that the company was granted an expanded indication for SMOFlipid(R) Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age. SMOFlipid can be used throughout the continuum of care, from hospital to home care settings.

Additionally, the presence of advanced healthcare facilities and favorable reimbursement policies and regulations in the region have led to a high hospital admission rate, which supports the overall high product demand for parenteral nutrition in North America.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American parenteral nutrition market.

Parenteral Nutrition Market key players:

Some of the key market players operating in the Parenteral Nutrition market include B. Braun SE, Fresenius Kabi India Pvt. Ltd, Baxter, Otsuka Pharmaceutical India Pvt. Ltd, Pfizer Inc, Grifols, S.A., JW Pharmaceutical, Aculife Healthcare, Kelun, American Regent, Inc, EuroLife Healthcare Pvt. Ltd, SGD Pharma, icumedical, Generic Specialties, Vifor Pharma Management Ltd, Amanta Healthcare, Anhui Medipharm Co, Ltd, and others.

Recent Developmental Activities in the Parenteral Nutrition Market:

• In May 2024, Baxter announced the US Food and Drug Administration (FDA) approval of Clinolipid (lipid injectable emulsion) for pediatric use, encompassing term and preterm neonates, to serve as a parenteral nutrition source of calories and essential fatty acids when oral or enteral nutrition is inadequate, contraindicated, or unavailable.
• In July 2021, Micrel Medical, a manufacturer of medical devices with a focus on infusion therapy, and Baxter Healthcare (Baxter) inked a contract, under which the businesses decided to market the infusion pump Micrel Mini Rythmic PN+ for parenteral nutrition (PN).

Key Takeaways from the Parenteral Nutrition Market Report Study

• Market size analysis for current parenteral nutrition market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the parenteral nutrition market.
• Various opportunities available for the other competitors in the parenteral nutrition market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current parenteral nutrition market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for parenteral nutrition market growth in the coming future?

Target Audience who can be benefited from this Parenteral Nutrition Market Report Study

• Parenteral Nutrition product providers
• Research organizations and consulting companies
• Parenteral Nutrition-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in parenteral nutrition
• Various end-users who want to know more about the parenteral nutrition market and the latest technological developments in the parenteral nutrition market.

Frequently Asked Questions for the Parenteral Nutrition Market:

1. What are parenteral nutrition?

Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that provides nutritional support to patients who are unable to utilize their gastrointestinal tract.

2. What is the market for parenteral nutrition?

The parenteral nutrition market was valued at USD 6,084.35 million in 2023 and is likely to register a CAGR of 6.04% during the forecast period from 2024 to 2030 to reach USD 8,614.69 million by 2030.

3. What are the drivers for the parenteral nutrition market?

The parenteral nutrition market is slated to witness prosperity owing to the increasing prevalence of malnutrition among children, rising government initiatives and issuance of new guidelines for parenteral nutrition, increasing prevalence of metabolic & chronic conditions, rising strategic steps by key players, rising new drug launches and approvals, and others will create a demand for the parenteral nutrition market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the parenteral nutrition market?

Some of the key market players operating in parenteral nutrition include B. Braun SE, Fresenius Kabi India Pvt. Ltd, Baxter, Otsuka Pharmaceutical India Pvt. Ltd, Pfizer Inc, Grifols, S.A, JW Pharmaceutical, Aculife Healthcare, Kelun, American Regent, Inc, EuroLife Healthcare Pvt Ltd, SGD Pharma, icumedical, Generic Specialties, Vifor Pharma Management Ltd, Amanta Healthcare, Anhui Medipharm Co, Ltd, and others.

5. Which region has the highest share in the parenteral nutrition market?

North America is expected to dominate the overall parenteral nutrition market during the forecast period from 2024 to 2030. This is due to the increasing prevalence of malnutrition and chronic diseases. Further, the increasing geriatric population base prone to chronic diseases, rising product development activities, and the presence of key domicile players in the region act as supportive factors for the North American parenteral nutrition market growth.

Table of Contents

1. Parenteral Nutrition Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Parenteral Nutrition Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Parenteral Nutrition Market Key Factors Analysis

• 5.1. Parenteral Nutrition Market Drivers
  • 5.1.1. The increasing prevalence of malnutrition among children
  • 5.1.2. Rising government initiatives and issuance of new guidelines for parenteral nutrition
  • 5.1.3. Increasing prevalence of metabolic & chronic conditions
• 5.2. Parenteral Nutrition Market Restraints and Challenges
  • 5.2.1. Lack of awareness regarding nutrition
  • 5.2.2. Stringent Approval Process
• 5.3. Parenteral Nutrition Market Opportunities
  • 5.3.1. Increasing approval of parenteral nutrition-related devices and drugs

6. Parenteral Nutrition Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Parenteral Nutrition Market Assessment

• 7.1. By Nutrient Type
  • 7.1.1. Carbohydrates
  • 7.1.2. Parenteral Lipid Emulsion
  • 7.1.3. Single-Dose Amino Acid Solution
  • 7.1.4. Trace Elements
  • 7.1.5. Vitamins & Minerals
• 7.2. By End-User
  • 7.2.1. Children & Newborns
  • 7.2.2. Adults
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Parenteral Nutrition Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Parenteral Nutrition Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.3.3. India Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Parenteral Nutrition Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Parenteral Nutrition Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Parenteral Nutrition Market Size in USD million (2021-2030)

8. Parenteral Nutrition Market Company and Product Profiles

• 8.1. B. Braun SE
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Fresenius Kabi India Pvt. Ltd
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Baxter
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Otsuka Pharmaceutical India Pvt. Ltd
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Grifols, S.A.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. JW Pharmaceutical
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Aculife Healthcare
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Kelun
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. American Regent, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. EuroLife Healthcare Pvt. Ltd
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. SGD Pharma
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. icumedical
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Generic Specialties
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Vifor Pharma Management Ltd.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Amanta Healthcare
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Anhui Medipharm Co, Ltd
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us